Intranasal immunotropic therapy for post-viral exudative otitis media in preschool children

Introduction. Improving the effectiveness of conservative treatment of secretory otitis media (SOM) in children remains an urgent problem because of the multifactorial etiology of the disease and the continued reliance on surgical intervention. The article presents the collective experience of monitoring the course of SOM after ARI with therapy aimed at various links in the pathogenesis of the disease.

Aim. To evaluate the clinical efficacy of intranasal azoximer bromide (Polyoxidonium ® , Petrovax, Russia) versus combination therapy with a mucoregulator, topical antibacterial agents, and a decongestant for the treatment of secretory otitis media in children after acute respiratory viral infection.

Materials and methods. A randomized, open-label, prospective, comparative clinical study was conducted in 49 children aged 4–7 years with SOM after ARI. The study group included 23 patients who received intranasal azoximer bromide, 3 drops in each nostril three times daily for two weeks. The control group comprised 26 patients who received combination therapy: an intranasal spray containing neomycin, polymyxin, dexamethasone metabenzoate, and phenylephrine (one administration per nostril three times daily for 10 days) plus oral carbocysteine at an age-appropriate dose for two weeks.

Results. During azoximer bromide treatment, the dynamics of intratympanic pressure recovery were not inferior to those with standard therapy, and SOM relapses were less frequent at 3 and 6 months.

Conclusions. Age-related characteristics of local immunity in children aged 4-7 years may underlie chronic catarrhal inflammation of the mucous membrane of the auditory tube and tympanic cavity after acute respiratory viral infection. Intranasal immunocorrection with azoximer bromide resolves catarrhal inflammation of the tympanic cavity and auditory tube during SOM developing after acute respiratory viral infection.

1. Kryukov AI, Ivoilov AI, Pakina BP, Yanovsky BB. A pathogenetic approach to the treatment of exudative otitis media in childhood. RMJ. 2013;(11):545. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Patogeneticheskiy_podhod_k_lecheniyu_ekssudativnogo_srednego_otita_v_detskom_vozraste/.

2. Polunin MM, Chernova OV. Treatment of exudative (secretory) otitis media in young children taking into account the anatomical features of the auditory tube. Vestnik Oto-Rino-Laringologii. 2020;85(1):10–13. (In Russ.) https://doi.org/10.17116/otorino20208501110.

3. Yang B, Brook CD. The Role of Allergy in Otologic Disease. Otolaryngol Clin North Am. 2017;50(6):1091–1101. https://doi.org/10.1016/j.otc.2017.08.005.

4. Orlova YE, Svistushkin VM, Nikiforova GN, Shevchik EA. Treatment principles of children with pharyngeal tonsil pathology in the background of allergic rhinitis (literature review): a review. Consilium Medicum. 2022;24(3):193–198. (In Russ.) https://doi.org/10.26442/20751753.2022.3.201516.

5. Савенко ИВ, Бобошко МЮ. Экссудативный средний отит. СПб.: Диалог; 2020. 168 с. Режим доступа: https://litres.uz/book/i-v-savenko/ekssudativnyy-sredniy-otit-57113516/.

6. Skovbjerg S, Roos K, Andersson M, Rabe H, Nilsson S, Lindh M, Wold AE. Inflammatory Mediator Profiles in Secretory Otitis Media in Relationship to Viable Bacterial Pathogens and Bacterial and Viral Nucleic Acids. J Interferon Cytokine Res. 2020;40(12):555–569. https://doi.org/10.1089/jir.2020.0075.

7. De Corso E, Cantone E, Galli J, Seccia V, Lucidi D, Di Cesare T et al. Otitis media in children: Which phenotypes are most linked to allergy? A systematic review. Pediatr Allergy Immunol. 2021;32(3):524–534. https://doi.org/10.1111/pai.13431.

8. Zolotova TV, Knyazeva OA, Davydova AP, Manchenkova II. Reccurence of exudative otitis media as a consequence of untreated pathology of the nasal cavity and nasopharynx. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2023;29(2):77–84. (In Russ.) Available at: https://www.elibrary.ru/rgbhio.

9. Liu W, Shi L, Feng Y. Advance in the pathogenesis of otitis media with effusion induced by platelet-activating factor. Sci Prog. 2024;107(4):368504241265171. https://doi.org/10.1177/00368504241265171.

10. Zhang Y, Liu J, Yang F, He Y, Yan S, Bai Y et al. COVID-19-related secretory otitis media in the omicron era: a case series. Eur Arch Otorhinolaryngol. 2023;280(10):4697–4700. https://doi.org/10.1007/s00405-023-08075-w.

11. Li DP, He M, Chai W, Huang H. The relationship between incidence of secretory otitis media and passive smoking in children. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31(15):1211–1213. https://doi.org/10.13201/j.issn.1001-1781.2017.15.018.

12. Chen J, Li W, Wen LT, Yang C, Sun CH, Qiu JH, Zha DJ. Crouzon syndrome with secretory otitis media: a case report and literature review. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;33(9):845–847. https://doi.org/10.13201/j.issn.1001-1781.2019.09.011.

13. Guo C, Pan L, Chen L, Xie J, Liang Z, Huang Y, He L. Investigating the epidemiological relevance of secretory otitis media and neighboring organ diseases through an Internet search. Peer J. 2024;12:e16981. https://doi.org/10.7717/peerj.16981.

14. Covelli E, Margani V, Trasimeni G, Filippi C, Bandiera G, Monini S, Barbara M. A case of cavernous hemangioma of the infratemporal fossa causing recurrent secretory otitis media. Braz J Otorhinolaryngol. 2022;88(6):999–1002. https://doi.org/10.1016/j.bjorl.2021.03.001.

15. Akcan FA, Dündar Y, Bayram Akcan H, Cebeci D, Sungur MA, Ünlü İ. The Association between Iron Deficiency and Otitis Media with Effusion. J Int Adv Otol. 2019;15(1):18–21. https://doi.org/10.5152/iao.2018.5394.

16. Padia R, Alt JA, Curtin K, Muntz HR, Orlandi RR, Berger J, Meier JD. Environmental contributions to otitis media requiring tympanostomy tubes. Int J Pediatr Otorhinolaryngol. 2017;101:97–101. https://doi.org/10.1016/j.ijporl.2017.07.035.

17. Svistushkin VM, Nikiforova GN, Shewchik EA, Zolotova AV. Otitis media with effusion – modern capabilities of conservative treatment. Rossiiskaya Otorinolaringologiya. 2014;2(69):153–161. Available at: https://cyberleninka.ru/article/n/ekssudativnyy-sredniy-otit-sovremennye-vozmozhnosti-konservativnogo-lecheniya.

18. Principi N, Marchisio P, Esposito S. Otitis media with effusion: benefits and harms of strategies in use for treatment and prevention. Expert Rev Anti Infect Ther. 2016;14(4):415–423. https://doi.org/10.1586/14787210.2016.1150781.

19. Rasheed AM. Is Topical Nasal Steroid Useful for Treatment of Otitis Media with Effusion in Children? Int Tinnitus J. 2023;27(1):62–67. https://doi.org/10.5935/0946-5448.20230011.

20. Gavrylenko YuV. Topical GCS drug “FLIX” efficacy in the treatment of secretory otitis media in children. Sovremennaya Pediatriya. 2018;2(90):91–96. (In Russ.) https://doi.org/10.15574/SP.2018.90.91.

21. Ikeda R, Hidaka H, Ito M, Kamide Y, Kuroki H, Nakano A et al. Pharmacotherapy focusing on for the management of otitis media with effusion in children: Systematic review and meta-analysis. Auris Nasus Larynx. 2022;49(5):748–754. https://doi.org/10.1016/j.anl.2022.03.017.

22. Xiaorong D, Li M, Xuefeng L, Jian H. Effects of dexamethasone combined with ambroxol hydrochloride on T-Cell subsets and hearing in patients with secretory otitis media. Pak J Pharm Sci. 2019;32:1437–1440. Available at: https://pubmed.ncbi.nlm.nih.gov/31551228/.

23. La Mantia I, Varricchio A, Ciprandi G. Allergen immunotherapy in children with otitis media with effusion: a preliminary experience. Eur Ann Allergy Clin Immunol. 2021;53(6):288–290. https://doi.org/10.23822/EurAnnACI.1764-1489.181.

24. Kaytez SK, Ocal R, Yumusak N, Celik H, Arslan N, Ibas M. Effect of probiotics in experimental otitis media with effusion. Int J Pediatr Otorhinolaryngol. 2020;132:109922. https://doi.org/10.1016/j.ijporl.2020.109922.

25. Simon F, Haggard M, Rosenfeld RM, Jia H, Peer S, Calmels MN, Couloigner V, Teissier N. International consensus (ICON) on management of otitis media with effusion in children. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135(1S):33–39. https://doi.org/10.1016/j.anorl.2017.11.009.

26. Hidaka H, Ito M, Ikeda R, Kamide Y, Kuroki H, Nakano A et al. Clinical practice guidelines for the diagnosis and management of otitis media with effusion (OME) in children in Japan – 2022 update. Auris Nasus Larynx. 2023;50(5):655–699. https://doi.org/10.1016/j.anl.2022.12.004.

27. Mileshina NA, Volodkina VV, Kurbatova EV, Osipenkov SS, Polunin MM, Chernova OV. The main steps in treatment of the children with otitis media with effusion. Vestnik Oto-Rino-Laringologii. 2021;86(6):31–34. (In Russ.) https://doi.org/10.17116/otorino20218606131.

28. El Feghaly RE, Jackson MA. Predicting Recurrent Acute Otitis Media and the Need for Tympanostomy: A Powerful Tool. Pediatrics. 2023;151(2):e2022060110. https://doi.org/10.1542/peds.2022-060110.

29. Zernotti ME, Pawankar R, Ansotegui I, Badellino H, Croce JS, Hossny E et al. Otitis media with effusion and atopy: is there a causal relationship? World Allergy Organ J. 2017;10(1):37. https://doi.org/10.1186/s40413-017-0168-x.

30. Sogebi OA, Oyewole EA, Ogunbanwo O. Asymptomatic Otitis Media With Effusion in Children With Adenoid Enlargement. J Natl Med Assoc. 2021;113(2):158–164. https://doi.org/10.1016/j.jnma.2020.08.005.

31. Galić MZ, Klančnik M. Adenoid size in children with otitis media with effusion. Acta Clin Croat. 2022;60(3):532–539. https://doi.org/10.20471/acc.2021.60.03.25.

32. Elzayat S, El-Deeb ME, El-Shirbeny HA, El-Shirbiny H, Abdel-Maboud M, Nasr K. The Prevalence and Association of Biofilms With Otitis Media With Effusion: A Systematic Review and Meta-Analysis. Ann Otol Rhinol Laryngol. 2024;133(2):229–238. https://doi.org/10.1177/00034894231188855.

33. Kulikova E, Golovko N, Chumakova A, Panchenko T. Treatment of secretory otitis media in children, depending on the stage of the process and on the background of the pathological conditions. Georgian Med News. 2019;(296):49–54. Available at: https://pubmed.ncbi.nlm.nih.gov/31889704/.

34. Paing A, Elliff-O’Shea L, Day J, Joshi D, Arnold S, Holland Brown T, Kennedy V. Modifiable risk factors for developing otitis media with effusion in children under 12 years in high-income countries: a systematic review. Arch Dis Child. 2024;110(1):45–51. https://doi.org/10.1136/archdischild-2024-327454.

35. Shcheplyagina LA, Kruglova IV. Vozrastnye osobennosti immuniteta u detej. RMJ. 2009;(23):1564. (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Vozrastnye_osobennosti_immuniteta_u_detey/.

36. Vavilova VP, Perevoshchikova NK, Rizo AA, Pavlenko SA, Filippova TV et al. Domestic immunomodulator Polyoxidonium in paediatric practice of treating pharyngeal lymphoid tissue ring pathology. Allergology and Immunology in Pediatrics. 2005;4:47–53. (In Russ.)

37. Prosekova EV, Netesova SYu, Zabelina NR, Sabynych VA, Sotnichenko SA. The cytokine profile structure of nasal secretion in children’s allergic rhinitis. Pacific Medical Journal. 2014;1:38–41. (In Russ.) Available at: https://www.tmj-vgmu.ru/jour/article/view/715/671.

38. Tataurshchikova NS, Sidorovich IG. The cytokine status as a criterion for the efficacy of intranasal aerosol therapy with the use of a cycloferon solution in the patients presenting with allergic rhinosinusitis. Vestnik Oto-Rino-Laringologii. 2012;77(3):79–82. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-otorinolaringologii/2012/3/030042-46682012321.

39. Vavilova VP, Chernyuk OS, Karaul’nova TA, Tarasova NI. New ways to influence local protective factors in children with pharyngeal lymphoid tissue ring pathology. Lechaschi Vrach. 2011;(6). (In Russ.) Available at: https://www.lvrach.ru/2011/06/15435224.